Bryan Garnier - Osmozis (ALOSM.PA) OSMOZIS: Positive management sentiment ahead of the summer | BUY | EUR6.7(+41%)

Report

Bryan Garnier

Eric Lemarie

OSMOZIS: Positive management sentiment ahead of the summer | BUY | EUR6.7(+41%)

OSMOZIS - BUY | EUR6.7(+41%)
Positive management sentiment ahead of the summer

Tourists back in campsites, including foreigners
Positive H1 EBITDA. FY above EUR2m looks achievable
Last quarter to be a key step. Acquisitions beyond are the plan.

27/05/2021 3 EN

Underlying

Osmozis

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Eric Lemarie

Other Reports on these Companies

Bryan Garnier

OSMOZIS - BUY | EUR9.5 VS. EUR8.3 (+22%) Bright year ahead

OSMOZIS - BUY | EUR9.5 VS. EUR8.3 (+22%) Bright year ahead Strong start of the year… … leading to revised estimates TP increased, investment case confirmed

January 14, 2022 January 14, 2022 1 EN

Bryan Garnier

OSMOZIS - BUY | EUR8.3 VS. EUR8 (+44%) Well placed to benefit from the energy and digital transition

OSMOZIS - BUY | EUR8.3 VS. EUR8 (+44%) Well placed to benefit from the energy and digital transition Solid profitability in 2020-21 Transformation of the group under way Further growth expected this year with EBITDA margin of 33% at least Buy reiterated, on the back of a positive momentum

December 15, 2021 December 15, 2021 4 EN

Bryan Garnier

OSMOZIS: Strong FY EBITDA margin expected after a good summer. | BUY | EUR8 VS. EUR6.7 (+34%)

OSMOZIS - BUY | EUR8 VS. EUR6.7 (+34%) Strong FY EBITDA margin expected after a good summer. A dynamic summer EUR2.5m of EBITDA reachable this year Solid mid-term guidance

October 13, 2021 October 13, 2021 4 EN

BICO: Q1 miss highlights near-term headwinds, placing under review

BICO’s Q1 2025 results underscore the early benefits of strategic streamlining under the BICO 2.0 plan: the gross margin improved to 54.0% (44.5%) despite a 17% YoY decline in revenues to SEK389m, coming 4% below CSS, reflecting a better product mix and enhanced cost discipline. Cash flow from oper

4m 4m 1 EN

Clement Genelot

Clement Genelot

Ceconomy: CEO surprise leave, what next?

With the CEO stepping down at short notice to become a federal minister, Ceconomy is entering a period of uncertainty. Far from the management instability and poor execution of the 2018-2021 era, we see the group in much better shape and hope for a smooth short-term interim with the current CFO sti

28m 28m 1 EN

Cedric Rossi ... (+3)

Cedric Rossi
Clement Genelot
Loic Morvan

On the shelves now: Consumer Weekly #67

In this Consumer Weekly newsletter, we provide a brief overview of the key factors affecting our Consumer coverage, from Luxury & Consumer goods to Retail & E-commerce and Food & Ingredients. This week, we look at the largest beauty groups in the world. Happy reading!

20h / 22m 20h / 22m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

OSMOZIS: Positive management sentiment ahead of the summer | BUY | EUR6.7(+41%)

OSMOZIS - BUY | EUR9.5 VS. EUR8.3 (+22%) Bright year ahead

OSMOZIS - BUY | EUR8.3 VS. EUR8 (+44%) Well placed to benefit from the energy and digital transition

OSMOZIS: Strong FY EBITDA margin expected after a good summer. | BUY | EUR8 VS. EUR6.7 (+34%)

BICO: Q1 miss highlights near-term headwinds, placing under review

Ceconomy: CEO surprise leave, what next?

On the shelves now: Consumer Weekly #67

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe